← Ticker index
BMY
Ticker
BMY
Bristol-Myers Squibb Company
Healthcare
Congressional Trades
102
by 16 members
Ticker disclosure brief
Congressional disclosure records for BMY
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
SELL · 2026-06-16
Largest range
$15K – $50K
Mike Kelly
Longest observed gap
318d
Valerie Hoyle
Highest 30d vs SPY
26.0%
Ro Khanna
Purchase rows
43
42%
Sale rows
56
55%
Disclosed midpoint
$1.2M
range estimate
Unique Traders
16
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats68 · 67%
Republicans34 · 33%
Federal awards
all →- 2026-07-07$138KDepartment of Veterans AffairsPOMALYST 2 MG, 3 MG,4 MG
- 2026-07-07$11KDepartment of Veterans AffairsPOMALYST 3 MG
- 2026-06-30$364KDepartment of Veterans AffairsEMERGENCY BREYANZI
- 2026-06-26$12KDepartment of Veterans AffairsPATIENT MEDICATION - THALIDOMIDE 100MG - SHIP TO BALTIMORE VA MEDICAL CENTER PHARMACY.
- 2026-06-18$16KDepartment of Veterans AffairsPOMALIDOMIDE(POMALYST) 4MG CAP
- 2026-06-16$364KDepartment of Veterans AffairsBREYANZI CAR T - TRANSPLANT
- 2026-06-16$364KDepartment of Veterans AffairsBREYANZI CAR T
- 2026-06-15$11KDepartment of Veterans AffairsPOMALYST 3 MG
- 2026-06-11$17KDepartment of Veterans AffairsPOMALYST 2 MG
- 2026-06-02$364KDepartment of Veterans AffairsBREAYNAZI FOR CAR-T TRANSPLANT MEDICATION
Lobbying filings
all →- 2026-07-09$60KBRISTOL-MYERS SQUIBB COMPANYIssues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
- 2026-04-20$1.3MBRISTOL-MYERS SQUIBB COMPANYH.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues
- 2026-04-20$80KBRISTOL-MYERS SQUIBB COMPANY340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
- 2026-04-20$80KBRISTOL-MYERS SQUIBBPolicies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
- 2026-04-20$60KBRISTOL-MYERS SQUIBBValue of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D, MFN U.S. Competitiveness issues
- 2026-04-20$60KBRISTOL-MYERS SQUIBB COMPANYIssues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process
- 2026-04-20$50KBRISTOL-MYERS SQUIBB COMPANYBiosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
- 2026-04-20$40KBRISTOL-MYERS SQUIBBIssues regarding approved and pipeline products, and related policy. 340 program issues. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy.
- 2026-04-20$30KBRISTOL-MYERS SQUIBB COMPANYEducation about the value of biopharmaceutical innovation and related issues.
- 2026-04-20$0BRISTOL-MYERS SQUIBB COMPANYIssues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform. Issues related to biosimilars reimbursement, supply chain and Medicare/Medicaid payment reform.
Loading trade analytics…
All Disclosed Trades
Page 3 · 25 of 102 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2025-06-24 | RVirginia Foxx | SELL | $1K – $15K | 7d | receipt → |
| 2025-06-24 | RVirginia Foxx | SELL | $1K – $15K | 7d | receipt → |
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 42d | receipt → |
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 41d | receipt → |
| 2025-05-19 | DRo Khanna | SELL | $1K – $15K | 22d | receipt → |
| 2025-05-19 | DRo Khanna | SELL | $1K – $15K | 22d | receipt → |
| 2025-04-15 | RTommy Tuberville | SELL | $1K – $15K | 31d | receipt → |
| 2025-04-15 | RTommy Tuberville | SELL | $1K – $15K | 30d | receipt → |
| 2025-04-15 | RTommy Tuberville | SELL | $1K – $15K | 30d | receipt → |
| 2025-04-01 | DJulie Johnson | SELL | $1K – $15K | 43d | receipt → |
| 2025-04-01 | DJulie Johnson | SELL | $1K – $15K | 43d | receipt → |
| 2025-03-27 | DGreg Landsman | SELL | $1K – $15K | 12d | receipt → |
| 2025-03-27 | DGreg Landsman | SELL | $1K – $15K | 12d | receipt → |
| 2025-01-15 | DJulie Johnson | BUY | $1K – $15K | 28d | receipt → |
| 2025-01-15 | DJulie Johnson | BUY | $1K – $15K | 28d | receipt → |
| 2024-12-06 | RVirginia Foxx | BUY | $1K – $15K | 31d | receipt → |
| 2024-12-06 | RVirginia Foxx | BUY | $1K – $15K | 31d | receipt → |
| 2024-12-06 | RVirginia Foxx | BUY | $1K – $15K | 31d | receipt → |
| 2024-02-22 | RByron Donalds | SELL | $1K – $15K | 260dApparent delay | receipt → |
| 2024-02-22 | RByron Donalds | SELL | $1K – $15K | 260dApparent delay | receipt → |
| 2024-08-05 | DRo Khanna | BUY | $1K – $15K | 32d | receipt → |
| 2024-08-05 | DRo Khanna | BUY | $1K – $15K | 32d | receipt → |
| 2024-01-18 | RJohn James | SELL | $1K – $15K | 228dApparent delay | receipt → |
| 2024-07-01 | DRo Khanna | BUY | $1K – $15K | 37d | receipt → |
| 2024-07-02 | DRo Khanna | BUY | $1K – $15K | 36d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.